Verastem 将来の成長

Future 基準チェック /26

Verastem is forecast to grow earnings and revenue by 25.8% and 57.1% per annum respectively while EPS is expected to grow by 41.3% per annum.

主要情報

25.8%

収益成長率

41.3%

EPS成長率

Biotechs 収益成長	27.1%
収益成長率	57.1%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	01 Nov 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:VSTM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	57	-99	-94	-95	8
12/31/2025	18	-120	-113	-109	9
12/31/2024	7	-106	-108	-130	9
6/30/2024	10	-89	-102	-102	N/A
3/31/2024	N/A	-106	-95	-94	N/A
12/31/2023	N/A	-87	-86	-86	N/A
9/30/2023	N/A	-77	-73	-73	N/A
6/30/2023	N/A	-75	-72	-72	N/A
3/31/2023	N/A	-73	-65	-65	N/A
12/31/2022	3	-74	-64	-64	N/A
9/30/2022	3	-73	-57	-57	N/A
6/30/2022	3	-78	-53	-53	N/A
3/31/2022	4	-73	-53	-53	N/A
12/31/2021	2	-71	-54	-54	N/A
9/30/2021	2	-75	-65	-65	N/A
6/30/2021	81	-39	-10	-10	N/A
3/31/2021	84	-45	-19	-19	N/A
12/31/2020	89	-68	-34	-34	N/A
9/30/2020	92	-87	-49	-49	N/A
6/30/2020	22	-130	-122	-122	N/A
3/31/2020	21	-149	-134	-134	N/A
12/31/2019	17	-149	-139	-139	N/A
9/30/2019	15	-122	-143	-120	N/A
6/30/2019	22	-113	-138	-115	N/A
3/31/2019	28	-89	-114	-91	N/A
12/31/2018	27	-72	-98	-75	N/A
9/30/2018	26	-79	-77	-76	N/A
6/30/2018	10	-81	-66	-65	N/A
3/31/2018	N/A	-76	N/A	-69	N/A
12/31/2017	N/A	-68	N/A	-57	N/A
9/30/2017	N/A	-61	N/A	-43	N/A
6/30/2017	N/A	-46	N/A	-37	N/A
3/31/2017	N/A	-41	N/A	-29	N/A
12/31/2016	N/A	-36	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-34	N/A
6/30/2016	N/A	-44	N/A	-39	N/A
3/31/2016	N/A	-51	N/A	-45	N/A
12/31/2015	N/A	-58	N/A	-46	N/A
9/30/2015	N/A	-60	N/A	-45	N/A
6/30/2015	N/A	-58	N/A	-43	N/A
3/31/2015	N/A	-55	N/A	-39	N/A
12/31/2014	N/A	-53	N/A	-37	N/A
9/30/2014	N/A	-51	N/A	-34	N/A
6/30/2014	N/A	-48	N/A	-32	N/A
3/31/2014	N/A	-45	N/A	-29	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VSTM is forecast to remain unprofitable over the next 3 years.

収益対市場: VSTM is forecast to remain unprofitable over the next 3 years.

高成長収益: VSTM is forecast to remain unprofitable over the next 3 years.

収益対市場: VSTM's revenue (57.1% per year) is forecast to grow faster than the US market (8.9% per year).

高い収益成長: VSTM's revenue (57.1% per year) is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if VSTM's Return on Equity is forecast to be high in 3 years time

Verastem 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Price target decreased by 8.5% to US$4.30

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Recent updates

Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as A Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $54.995002 million.

Verastem Oncology Announces First Patient Dosed with Gfh375/Vs-7375 in A Phase 1/2 Trial in China as Part of Collaboration with Genfleet Therapeutics

Verastem: Narrowed Market And Less Compelling Efficacy Warrant Rating Downgrade

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer

Verastem Oncology Announces Executive Changes

Verastem, Inc., Annual General Meeting, May 23, 2024

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers

Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem Oncology Announces the Launch of the New Healthcare Professional Component

Verastem, Inc. has filed a Follow-on Equity Offering in the amount of $6.510455 million.

Verastem Oncology Announces Executive Appointments

Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ in KRAS G12C-Mutant Non-Small Cell Lung Cancer

Verastem, Inc. Appoints Daniel Paterson as Class III Director

Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer, Effective August 1, 2023

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Verastem, Inc. has completed a Follow-on Equity Offering in the amount of $85.018462 million.

Verastem Oncology Announces 1-for-12 Reverse Stock Split to Satisfy the Price Requirement for Continued Listing on the Nasdaq Global Market

-Verastem Oncology Appoints Karin Tollefson to Board of Directors

Price target decreased by 9.3% to US$3.25

Price target decreased by 11% to US$3.79

Verastem, Inc. announced that it expects to receive $59.995963 million in funding from BVF Partners L.P.

Price target decreased by 8.5% to US$4.30

Verastem, Inc. announced that it expects to receive $60 million in funding

Verastem Oncology Appoints Rob Gagnon to the Board of Directors

Less than half of directors are independent

Consensus forecasts updated

Price target decreased to US$4.70

Price target decreased to US$4.75

Verastem Oncology Appoints Anil Kapur to Board of Directors

Verastem Oncology Announces RAMP VS-6766 Clinical Trials

Verastem: Moving Forward

Health Check: How Prudently Does Verastem (NASDAQ:VSTM) Use Debt?

Second quarter 2022 earnings released: US$0.12 loss per share (vs US$0.098 loss in 2Q 2021)

Verastem Non-GAAP EPS of -$0.11 in-line

Verastem: Looking Increasingly Attractive

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 2000 Dynamic Index

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 +/- Defactinib in Low-Grade Serous Ovarian Cancer

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$5.40

Less than half of directors are independent

Verastem: Time To Take My Position Out Of Mothball

Price target decreased to US$5.50

Consensus forecasts updated

Verastem, Inc., Annual General Meeting, May 12, 2022

Less than half of directors are independent

No longer forecast to breakeven

Verastem, Inc. Announces Management Changes

Vectoring In On Verastem

CEO & Director recently sold US$53k worth of stock

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$0.078 profit in 3Q 2020)

Verastem: Buying Opportunity Following Unjustified Sell-Off

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.098 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2023

Verastem, Inc.(NasdaqGM:VSTM) dropped from Russell 3000E Value Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘